Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
Grant seeks to understand schizophrenia emergence in mid to late-life for improved prevention and treatment.
Funder: National Institutes of Health
Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; project period max 2 years.
Summary: Supports translational research to understand the emergence and trajectory of schizophrenia and related psychotic disorders in individuals aged 35 and older, aiming to identify targets for prevention and treatment.
Key Information: Applications must focus on mid- to late-life (≥35 years); non-domestic (non-U.S.) entities are eligible; clinical trial optional; strict data sharing via NIMH Data Archive required.
Description
This NIH funding opportunity supports exploratory/developmental (R21) research projects that advance understanding of the mechanisms underlying the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life (defined as age 35 and above). The goal is to identify neurobiological, behavioral, psychosocial, and environmental mechanisms that can inform future prevention and intervention strategies for this population.
Research may address first-episode psychosis in mid- to late-life, mechanisms of symptom progression, risk of dementia, accelerated biological aging, social determinants of health, resilience, and recovery. Projects may use innovative methods, including neuroimaging, computational approaches, and multi-level analyses, but must not be limited to a single level of analysis.
This opportunity is open to both clinical trial and non-clinical trial applications. Projects that are high-risk/high-reward and lack preliminary data are especially encouraged under the R21 mechanism.
